Journal ArticleDOI
Overcoming a Positive Crossmatch in Living-Donor Kidney Transplantation
James M. Gloor,Steven R. DeGoey,Alvaro A. Pineda,S. Breanndan Moore,Mikel Prieto,Scott L. Nyberg,Timothy S. Larson,Matthew D. Griffin,Stephen C. Textor,Jorge A. Velosa,Thomas R. Schwab,Lynette Fix,Mark D. Stegall +12 more
Reads0
Chats0
TLDR
It is suggested that selected crossmatch‐positive patients can be transplanted successfully with living‐donor kidney allografts, using a protocol of pretransplant plasmapheresis, intravenous immunoglobulin, rituximab and splenectomy.About:
This article is published in American Journal of Transplantation.The article was published on 2003-08-01. It has received 252 citations till now. The article focuses on the topics: Transplantation & Kidney transplantation.read more
Citations
More filters
Journal ArticleDOI
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Ashley Vo,Marina Lukovsky,Mieko Toyoda,Jennifer Wang,Nancy L. Reinsmoen,Chih-Hung Lai,Alice Peng,Rafael Villicana,Stanley C. Jordan +8 more
TL;DR: Findings suggest that the combination of intravenous immune globulin and rituximab may prove effective as a desensitization regimen for patients awaiting a transplant from either a living donor or a deceased donor.
Journal ArticleDOI
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
TL;DR: A need for controlled clinical trials is clearly indicated before the widespread use of this drug in transplant, and the history, pharmacokinetics and potential mechanism of action of rituximab are reviewed.
Journal ArticleDOI
Antibody-mediated organ-allograft rejection
Robert B. Colvin,R. Neal Smith +1 more
TL;DR: Antibody induces rejection acutely through the fixation of complement, resulting in tissue injury and coagulation, and complement activation recruits macrophages and neutrophils, causing additional endothelial injury.
Journal ArticleDOI
Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) Conference
M. Abecassis,Stephen T. Bartlett,Allan J. Collins,Connie L. Davis,Francis L. Delmonico,John J. Friedewald,Rebecca Hays,Andrew Howard,Edward R. Jones,A. B. Leichtman,Robert M. Merion,Robert A. Metzger,Francoise Pradel,Eugene J. Schweitzer,Ruben L. Velez,Robert S. Gaston +15 more
TL;DR: With implementation of early education, referral to a transplant center coincident with creation of vascular access, timely transplant evaluation, and identification of potential living donors, early transplantation can be an option for substantially more patients with chronic kidney disease.
Journal ArticleDOI
A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody
TL;DR: It is concluded that multiple plasmapheresis‐based regimens leads to more reproducible desensitization and lower humoral rejection rates than a single high‐dose of IVIG, but that no regimen was completely effective in preventing humoral rejected.
References
More filters
Journal ArticleDOI
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients
Robert A. Montgomery,Andrea A. Zachary,Lorraine C. Racusen,Mary S. Leffell,Karen E. King,James F. Burdick,Warren R. Maley,Lloyd E. Ratner +7 more
TL;DR: This protocol shows promise for eliminating DSA preemptively among patients with low-titer positive antihuman globulin-enhanced, complement-dependent cytotoxicity cross-matches, allowing the successful transplantation of these patients using a live donor without any cases of HAR.
Journal ArticleDOI
Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg)
Denis Glotz,Corinne Antoine,Pierre Julia,Caroline Suberbielle-Boissel,Samir Boudjeltia,Rabah Fraoui,Chafic Hacen,Alain Duboust,Jean Bariety +8 more
TL;DR: It is shown that administration of intravenous immunoglobulins (IVIg) can induce a profound and sustained decrease in the titers of anti‐HLA antibodies, which allows safe and prompt kidney transplantation of immunized patients.
Journal ArticleDOI
Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.
TL;DR: Biochemical studies to determine the effective component of IVIG show that it is the IgG fraction and not soluble antigen or the minor IgM or IgA contaminants that is responsible, which suggests an antiidiotypic modulation of anti-HLA antibodies in vitro and in vivo.
Journal ArticleDOI
ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.
James M. Gloor,Donna J. Lager,S. Breanndan Moore,Alvaro A. Pineda,Mary E. Fidler,Timothy S. Larson,Joseph P. Grande,Thomas R. Schwab,Matthew D. Griffin,Mikel Prieto,Scott L. Nyberg,Jorge A. Velosa,Steven C. Textor,Jeffrey L. Platt,Mark D. Stegall +14 more
TL;DR: ABO-incompatible living donor kidney transplants can achieve an acceptable 1-year graft survival rate using an immunosuppressive regimen consisting of Thymoglobulin induction, tacrolimus, mycophenolate mofetil, and prednisone combined with pretransplant plasmapheresis, intravenous immunoglobulus, and splenectomy.
Journal ArticleDOI
Flow Cytometric Crossmatching in Primary Renal Transplant Recipients with a Negative Anti-Human Globulin Enhanced Cytotoxicity Crossmatch
Martin Karpinski,David N. Rush,John Jeffery,Markus Exner,Heinz Regele,Silvia Dancea,Denise Pochinco,Patricia E. Birk,Peter Nickerson +8 more
TL;DR: In primary renal transplant recipients with a negative T cell AHG-CDC crossmatch and a negative B cell CDC crossmatch pretransplant, a positive FCXM is associated with an increased risk of early graft loss due to antibody-mediated rejection and may represent a relative contraindication to transplantation.
Related Papers (5)
Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease: Report of the NIH IG02 Trial
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.
Lorraine C. Racusen,Robert B. Colvin,Kim Solez,Michael J. Mihatsch,Philip F. Halloran,Patricia Campbell,Michael Cecka,Jean Pierre Cosyns,Anthony J. Demetris,Michael C. Fishbein,Agnes B. Fogo,Peter N. Furness,Ian W. Gibson,Denis Glotz,Pekka Häyry,Lawrence Hunsickern,Michael Kashgarian,Ronald H. Kerman,Alex J. Magil,Robert A. Montgomery,Kunio Morozumi,Volker Nickeleit,Parmjeet Randhawa,Heinz Regele,Daniel Serón,Surya V. Seshan,Stale Sund,Kiril Trpkov +27 more